Provider review
BloomMD review
By The Dose Brief Desk · Updated
BloomMD’s semaglutide page presents several supply options and inconsistent headline amounts; the selected variant determines the useful price.
Not rated. This review examines published program information; it is not a firsthand treatment review.
At a glance
- Semaglutide
- Page shows $275 headline; $295 monthly, $750/90 days and $395/10-week starter variants
- Tirzepatide
- Current product-specific quote not verified
- Availability
- Product instructions identify state-specific differences; confirm eligibility.
- Treatment formats
- Compounded semaglutide with glycine and B12, injectable.
Obtain the selected variant’s total and recurring-payment schedule before ordering.
The headline and variants need reconciliation
BloomMD’s semaglutide product page shows a $275 headline alongside options labeled $295 monthly at any dose, $750 for 90 days and $395 for a ten-week new-patient supply. These should not be collapsed into one starting monthly price. Ask which selected variant controls your order.
Compare supply periods carefully
Ten weeks, 90 days and a monthly plan cover different lengths of care. Have the clinician confirm the prescribed quantity and how later dose changes affect remaining supply. A longer purchase may reduce ordering frequency, but only the actual plan terms can establish savings.
How approval and support work
BloomMD describes buying before clinical review, a refund if treatment is declined, and included supplies, shipping and ongoing messaging. Its page identifies differences for California, Indiana and Minnesota. Confirm the formulation and care process for your location rather than assuming every variant is available everywhere.
Resolve recurring billing before paying
A recurring-purchase disclaimer appears on the page. Obtain the next-charge date, cancellation cutoff and rules for medication already sent to the pharmacy. The named dispensing pharmacy and a comparable tirzepatide offer were not established in the reviewed material.
What stands out
- Several supply lengths are explicitly offered
- Clinical-denial refund and messaging are described
What to check
- Headline and variant prices do not fully agree
- Recurring-order and pharmacy details need clarification
Sources and review scope
Public information checked in October 2026. Prices and eligibility can change. We have not enrolled in treatment, independently tested medications or verified the licenses of the clinicians and pharmacies involved in an individual prescription. Compounded medications are not FDA-approved; studies of approved brands do not establish that a compounded product has the same safety or effectiveness.